An Ohio State-led pilot is giving psychedelic medicine its biggest veteran PTSD headline yet: nine of 12 veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria one month after supervised psilocybin therapy. The result is striking, but the study is small, open-label, and not a green light for self-medicating with mushrooms.
The study, reported today by The Independent, is described as the first formal trial of psilocybin therapy specifically involving veterans with PTSD. Three participants did not reach remission, although two showed some improvement and one experienced little change.
This was not a casual dose-and-see-what-happens experiment. According to the researchers’ conference abstract, the 12 veterans completed eight hours of preparation therapy, received two doses of synthetic psilocybin — 15 milligrams and 25 milligrams — and then completed eight hours of integration therapy.
The 11-week protocol was designed primarily to evaluate safety, not prove that psilocybin works as a PTSD treatment. The most common reported side effect was a mild headache, and the researchers reported no serious adverse effects or increase in suicidality in the study sample.
The Results Are Promising, But The Trial Was Tiny
Lead researcher Alan Davis cautioned that the findings need to be tested in larger randomized clinical trials, according to The Independent. Because participants knew they were receiving psilocybin and there was no comparison group, researchers cannot fully separate the drug’s effects from expectations, therapy, or the unusual intensity of the treatment experience.
The Department of Veterans Affairs’ National Center for PTSD says psychedelic-assisted therapy remains experimental, even as psilocybin and MDMA receive growing research attention. Standard protocols generally combine preparation, a closely supervised medicine session and follow-up integration — meaning the therapy around the drug is not an optional accessory.
Federal Agencies Are Moving Faster On Psychedelic Research
The timing is politically significant. On July 13, the U.S. Department of Health and Human Services and the Department of Veterans Affairs announced a five-year partnership to expand veteran participation in clinical research, train providers and prepare for possible future FDA-approved psychedelic treatments, according to HHS.
The Food and Drug Administration also announced in April that it was prioritizing development of several psychedelic-related treatments, including psilocybin programs for treatment-resistant depression and major depressive disorder. The agency emphasized that faster review and permission to conduct research do not mean any of those drugs have been approved as safe or effective.
That federal push is already showing up in the VA system. Hoodline reported in June that Edward Hines Jr. VA Hospital near Chicago had begun enrolling veterans in a federally authorized psilocybin-assisted therapy trial, joining VA research sites in Houston, New York and San Francisco.
What The Study Does Not Change Yet
Psilocybin remains a Schedule I controlled substance under federal law, and this pilot does not create a prescription pathway for veterans or anyone else. The study also used measured, synthetic psilocybin in a structured clinical setting — not unregulated mushrooms, recreational use or an at-home treatment plan.
Researchers plan to follow the participants for up to six months and seek funding for a larger randomized trial. For now, the Ohio State results are best read as an unusually encouraging signal that supervised psychedelic-assisted therapy deserves more rigorous testing, not as a finished treatment breakthrough.
